Holm-Jorgensen Rasmus
SEC insider (Form 3/4/5 filer). CIK 0001950496. Chief Financial Officer at Acrivon Therapeutics, Inc. (ACRV). 4 reported Form 4/5 transactions since Sep 2024; latest on Mar 1, 2025. Located in WATERTOWN, MA.
Companies Holm-Jorgensen Rasmus has filed insider reports for
- Acrivon Therapeutics, Inc. (ACRV): Officer, Chief Financial Officer
Holm-Jorgensen Rasmus
CIK: 0001950496
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ACRV
Acrivon Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Mar 1, 2025ACRV
Acrivon Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
109.3K shares- - Feb 14, 2025ACRV
Acrivon Therapeutics, Inc.
Tax PaymentDirect434 shares at avg. $5.42$2K - Nov 14, 2024ACRV
Acrivon Therapeutics, Inc.
Tax PaymentDirect368 shares at avg. $7.92$3K - Mar 1, 2024ACRV
Acrivon Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
90.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 1, 2025 | ACRV Acrivon Therapeutics, Inc. | Award Stock Option (Right to Buy) | 109,309 | - | - | Direct |
| Feb 14, 2025 | ACRV Acrivon Therapeutics, Inc. | Tax Payment | 434 | $5.42 | $2,352 | Direct |
| Nov 14, 2024 | ACRV Acrivon Therapeutics, Inc. | Tax Payment | 368 | $7.92 | $2,915 | Direct |
| Mar 1, 2024 | ACRV Acrivon Therapeutics, Inc. | Award Stock Option (Right to Buy) | 90,090 | - | - | Direct |
1-4 of 4 transactions